The Swiss stock exchange is expected to welcome a new addition in the coming week.
The medical technology provider Skan Group announced an IPO on the SIX for October 28th.
Skan offers the shares in a range of 44 to 55 francs per title.
Measured against the middle of the range, Skan has a market value of around 1.1 billion francs (around one billion euros).
Shortly after the offer period began, one of the banks involved in the transaction reported that there were more subscriptions than there were shares available.
As part of the IPO, Skan wanted to raise around 90 million francs gross with a capital increase, it said.
In addition, the current majority shareholder Willy Michel and other owners would sell existing stocks.
In total, shares with a value of up to CHF 270 million could come onto the market.
In return for a guaranteed allotment, the fund house M&G Investments has committed itself to subscribe for securities worth 35 million euros as an anchor shareholder.
After the IPO, the free float should amount to around 50 percent.
The debut will be organized by Credit Suisse and Berenberg.
Fourth new addition to SIX
Skan, which emerged from the holding company BV Group, specializes in clean room equipment and isolators for the pharmaceutical industry and achieved sales of 207.3 million francs and an operating profit (Ebitda) of 34.4 million last year.
The sales of the company from Allschwil near Basel grew by an average of 30.5 percent over the past three years.
After the Sulzer spin-off Medmix, the aircraft supplier Montana Aerospace and the pharmaceutical supplier Polypeptide, Skan would be the fourth new addition to SIX this year.
The IPOs of watch retailer Chronext and other companies were recently called off in the face of headwinds in the financial markets.